Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study)

Erythropoietin in Methanol Associated Optic Neuropathy

Methanol poisoning could result in severe optic neuropathy, profound visual loss and finally optic atrophy and permanent, irreversible optic atrophy and visual loss. Erythropoietin (EPO) has recently emerged as a drug that may help retinal ganglion cell loss and improve optic nerve function in some acquired types of optic neuropathy including traumatic optic neuropathy ,ischemic optic neuropathy and optic neuritis .It has been found that EPO offer some protection to the optic nerve and retina when they are injured and apoptosis process starts in retinal ganglion cells. The standard treatments of methanol poisoning are reanimation, metabolic stabilization, and inhibition of alcohol dehydrogenase by antagonist agents and elimination of toxic metabolites in early phase of toxicity by dialysis. However, after established optic neuropathy and visual loss there is little chance, if any, for visual recovery and no definitive treatment exist for treatment in these cases. The investigators recently reported the investigators preliminary results on 16 cases with methanol poisoning and found a beneficial effect of systemic erythropoietin in methanol associated optic neuropathy. Now, the investigators aim to investigate the effect of this agent in a clinical trial.

The purpose of this study is to determine if EPO could improves optic nerve function and help patients to improve visual recovery after methanol poisoning. Primary outcome measure would be best-corrected visual function and secondary outcome measure is ocular coherence tomography (OCT) measure of mean peripapillary nerve fiber layer thickness. Results of this study could be very valuable in formulating an evidence-based management of Methanol Associated Optic Neuropathy(MAON) and provide a high level evidence for changing the practice on management of methanol poisoning . Also it could provide valuable data for neuroprotective effects of erythropoietin specifically in neuroscience and ophthalmology.

The EPO-MAON trial is designed as a randomized, controlled, observer, and interpreter blinded mono-center pilot trial with two parallel groups and a primary endpoint of best corrected visual acuity during 120 days after enrollment into treatment groups.

All patients with methanol poisoning referred to Farabi hospital will be examined and evaluated for best-corrected visual acuity, pupillary light reflexes, relative afferent pupillary defect, color vision (Ishihara plates), fundus photography, slit lamp exam of anterior segment and fundus exam with 78 D lens.

Study Overview

• Status: Unknown
• Conditions: Optic Nerve Diseases
• Intervention / Treatment: Drug: Erythropoietin; Other: placebo

• Study Type: Interventional
• Enrollment (Anticipated): 24
• Phase: Phase 3

Contacts and Locations

Study Locations

• Iran, Islamic Republic of
  • Tehran, Iran, Islamic Republic of, 1336616351
    • Farabi Hospital, Tehran University of Medical Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 10 years to 50 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients with confirmed MAON
2. age 10-50 years old
3. Best Corrected Visual Acuity(BCVA)<20/30 or Visual field defect in 10 degrees of central fixation shown in visual field perimetry C-24 SITA(Swedish interactive threshold algorithm)
4. those who can respond to questions and undergo diagnostic tests.

Exclusion Criteria:

1. previous intra-ocular or ocular surface surgeries;
2. those who do not agree to perform ophthalmic exams explained to them by the examiner ophthalmologists
3. those who have history of diabetes mellitus, cardiovascular disease, cerebrovascular disease.
4. Those who had received corticosteroid within past 1 month.
5. Those who has any cornea, lens, retina, optic nerve, choroid or central nervous system(CNS) disease that could potentially affect visual function.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: EPO; 20,000 IU recombinant human erythropoietin IV infusion in 100 ml normal saline in 2 hr for 3 successive days	Drug: Erythropoietin; 20,000 IU epo IV infusion in 100 ml normal saline in 2 hr for 3 successive days
Placebo Comparator: control group; 100 ml normal saline in 2 hr for 3 successive days	Other: placebo; 100 ml normal saline in 2 hr for 3 successive days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Best Corrected Visual Acuity	centra visual acuity changes from baseline by C Landolt chart after refractive error correction and pinhole if not corrected by glasses alone-converted to logMAR by special prepared table	changes from baseline at week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
peripapillary nerve fiber layer thickness	thickness of peripapillary nerve fiber layer using spectral domain OCT	changes from baseline at week 12

Collaborators and Investigators

• Sponsor: Tehran University of Medical Sciences
• Collaborators: Iran University of Medical Sciences

Study record dates

Study Major Dates

• Study Start: March 1, 2015
• Primary Completion (Actual): March 30, 2019
• Study Completion (Anticipated): March 30, 2020

Study Registration Dates

• First Submitted: February 17, 2015
• First Submitted That Met QC Criteria: February 24, 2015
• First Posted (Estimate): March 3, 2015

Study Record Updates

• Last Update Posted (Actual): March 10, 2020
• Last Update Submitted That Met QC Criteria: March 9, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Keywords: Erythropoietin -Methanol - Optic Neuropathy
• Additional Relevant MeSH Terms: Eye Diseases; Cranial Nerve Diseases; Nervous System Diseases; Optic Nerve Diseases; Hematinics; Epoetin Alfa
• Other Study ID Numbers: ERS139

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided